✦ LIBER ✦

SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia

✍ Scribed by Baccarani, M

Book ID: 110053886
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 26 KB
Volume: 12
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2401063

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hypersensitivity of bcr-abl-positive pro

Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia

✍ Thijsen, S F T; van Oostveen, J W; Schuurhuis, G J; Theijsmeijer, A P; Oudejans, 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 272 KB

Major molecular response to imatinib in

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

✍ Tchirkov, A; Couderc, J-L; Périssel, B; Goumy, C; Regnier, A; Uhrhammer, N; Verr 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 94 KB

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o